Although these fitness trade-off scenarios are commonly observed in natural and experimental systems, few studies have focused on their underlying mechanisms. Some of these trade-off scenarios are observed in drug-resistant isolates of C. albicans. Evidence of AP in drug-resistant mechanisms was observed in a single isolate from our recent evolutionary study of C. albicans (Huang et al., 2011). In this study, cell populations were evolved under the selective pressures of fluconazole and limiting carbon source (glucose). An adaptive clone isolated from one population (DP-1-M5) showed a significant increase in the relative fitness compared to the parental strain in the presence

of MG-132 mw drug, but the increased drug resistance had a fitness cost, as the mutant showed a lower relative fitness in the absence of the drug (Table 1), demonstrating a clear case of AP. However, the majority of the isolates from this study fall in the IA or CA categories described above, where mutations that are beneficial in the presence of the drug are either neutral or beneficial in the absence of the drug (see Table 1). This is contrary to results from Cowen et al. (2001); in their study, most isolates with DNA Damage inhibitor increased fitness

in the presence of the drug compared with the parental strain showed neutral or negative fitness in the absence of the drug (AP or IA). Possible explanations for the difference in our observations may be due to the differences in C. albicans strains used for the evolution experiments, the media used for the evolution (yeast nitrogen base vs. RPMI 1640), and the population size and evolution system used (chemostat vs. serial batch transfer). The use of serial batch transfer involves a larger bottleneck effect during each transfer. Thus, it is likely that the majority of the beneficial mutations that arise are lost in the process. In a continuous system, on the other hand, beneficial mutants have a higher probability of being retained in the system for further evolution. However, the exact mechanisms for the fitness trade-offs will require further studies

to identify all the underlying adaptive mutations and to characterize their exact fitness effects. Both in vivo and in vitro data have shown C. albicans populations to be heterogeneous and that clonal interference plays Edoxaban an important role in the population structure during exposure to antifungal agents. With the development of VERT, we can now track the population dynamics during adaptive evolution to readily estimate the frequency at which drug-resistant mutants arise in the population and to isolate mutants in a systematic manner. While clinical isolates from patients throughout the course of treatment would be the ideal system to study the emergence of antifungal drug resistance, it is difficult and often not practical to control. In vitro systems using bioreactors offer controlled and more reproducible environments.